Drug Patent Watch
OCTOBER 4, 2021
This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…. The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
OCTOBER 8, 2021
Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Bill and Eric discuss the complexities of digital patient support program technologies and introduce TrialCard’s integrated suite of solutions. To learn more, please contact Trialcard at sales@trialcard.com or visit them in booth #416 at the upcoming Asembia Specialty Pharmacy Summit from October 26 to 29, 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Strateos Blog: Drug Discovery
OCTOBER 8, 2021
Strateos was pleased to sponsor a webinar on Sept 27, 2021 to discuss how a single unified cloud-based software platform can overcome current operational inefficiencies in life science R&D labs. Alok Gupta, SVP of Engineering, Venkat (VK) Eswarakrishanan, Product Manager, and Vanessa Biggers, Director of Engineering, Scientific Technologies at Strateos led the discussion.
The Pharma Data
OCTOBER 8, 2021
Today, the U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients with congenital athymia, a rare immune disorder. Rethymic is the first thymus tissue product approved in the U.S. “Today’s action marks the first FDA approval of a therapy to treat this very rare and devastating disease in children,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “We remain committed to helping ad
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
OCTOBER 3, 2021
This chart shows the pharmaceutical companies with the most solution dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most solution dosed drugs…. The post Which pharmaceutical companies have the most solution dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
The Connected Lab
OCTOBER 6, 2021
Exploring how digital transformation will revolutionize process optimization and decision-making within the pharmaceutical industry Digital transformation is ushering in a new era for pharmaceutical research and manufacturing, characterized by advanced solutions, such as automation, networked technologies and machine learning, that support faster decision-making and more efficient process control.
The Pharma Data
OCTOBER 7, 2021
COVID-19 vaccines are highly effective in preventing symptomatic illness among health care workers in real-world settings. The study, published in the New England Journal of Medicine, found that health care personnel who received a two-dose regimen of Pfizer-BioNTech vaccine had an 89% lower risk for symptomatic illness than those who were unvaccinated.
Drug Patent Watch
OCTOBER 8, 2021
This chart shows the pharmaceutical companies with the most patents in European Patent Office. Patents must be filed in each country (or, in some cases regional patent office) where patent…. The post Which pharmaceutical companies have the most drug patents in European Patent Office? appeared first on DrugPatentWatch - Make Better Decisions.
Crown Bioscience
OCTOBER 5, 2021
Review key questions on preclinical models and rare cell analysis technology for assessing CAR-T cell therapies from our recent webinar , answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Nvidia Developer: Drug Discovery
OCTOBER 5, 2021
A new study out of the Massachusetts Institute of Technology (MIT) could arm healthcare workers with the information needed to effectively treat COVID-19. A new study out of the Massachusetts Institute of Technology (MIT) could arm healthcare workers with the information needed to effectively treat COVID-19 patients. Recently published in the Proceedings of the National Academy of Sciences , the research develops a deep learning model that determines the best drug combinations for fighting the v
The Pharma Data
OCTOBER 7, 2021
Research shows the origin of medicines becomes more important. AMSTERDAM–(BUSINESS WIRE)– The pandemic has triggered a greater interest among patients about Europe’s role in medicine manufacturing. New research just revealed show that 7 in 10 patients now want to know where their drugs are made as the pandemic has exposed weaknesses in the growing concentration of essential medicine production overseas.
Drug Patent Watch
OCTOBER 7, 2021
This chart shows the companies which have received the most pediatric exclusivities in the past five years. Pediatric exclusivity is granted to drug companies for conducting pediatric studies on their…. The post Pharmaceutical companies with the most ‘Pediatric Exclusivity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
The ChEMBL-og
OCTOBER 4, 2021
Over the years we've added many new features to ChEMBL and some of these have proved to be particularly valuable to our users. However, our resources are finite, and in order to continue to bring you exciting new improvements, we may sometimes need to re-evalutate features that are not well used and/or costly to maintain. To get the clearest possible view of which of our current data types, formats and access mechanisms are most important to you, we've put together a brief survey.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Crown Bioscience
OCTOBER 2, 2021
Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most popular questions from his recent syngeneic model webinar , covering the latest research, model developments , and platforms for moving past syngeneics for advanced immuno-oncology studies.
The Pharma Data
OCTOBER 6, 2021
Pfizer and BioNTech today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18?years of age and older. The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the
Drug Patent Watch
OCTOBER 6, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
OCTOBER 4, 2021
Informa Connect’s Rare Disease Innovation & Partnering Summit. Hybrid Event. In person: December 6-10 | Boston, MA. Virtual: December 9-10 www.informaconnect.com/raredisease. Exclusive Offer – Be sure to use your exclusive promo code DC4RARE10 to save 10% off* of your registration. After over a year apart, Informa Connect is pleased to announce that Rare Disease Innovation & Partnering Summit will return this Winter as a hybrid event, in-person December 6-7 in Boston, MA and virtually De
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
The Pharma Data
OCTOBER 6, 2021
GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK’s RTS,S malaria vaccine to reduce childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission as defined by WHO. RTS,S is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce malaria in children.
The Pharma Data
OCTOBER 6, 2021
Merck, known as MSD outside the United States and Canada, in collaboration with the bone cancer advocacy community and Emmy- nominated actress, Yvonne Orji, launched a new aggressiveness, Uncovering TNBC, to exfoliate light on the unique challenges Black women face when diagnosed with threefold-negative bone cancer (TNBC). Non-Hispanic Black women are much two times more likely to have TNBC thannon-Hispanic white women, and compared to white women, Black women are more likely to die of the ailme
The Pharma Data
OCTOBER 6, 2021
Early-stage research suggests potential to prevent and treat all dengue serotypes With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing. [1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats. The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven C
The Pharma Data
OCTOBER 6, 2021
Takeda Pharmaceutical Company Limited today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has suspended dosing of patients and has decided to stop both Phase 2 studies early. This allows for the timely interpretation of the benefit /risk profile of TAK-994 and to determine next steps for the program.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
OCTOBER 6, 2021
First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older Timely new data for the start of the influenza vaccination campaigns across the Northern Hemisphere. Interim results from the first co-administration descriptive study of Sanofi’s Fluzone ® High-Dose Quadrivalent vaccine with Moderna’s COVID-19 mRNA investigational booster dose show that the administration of the vaccine
The Pharma Data
OCTOBER 6, 2021
Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta ® (ofatumumab) and Mayzent ® (siponimod) Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remibrutinib is a highly selective, potent oral BTK inhibitor with a potential best-in-class profile 1 Late-breaking safety data will be presented, including outcomes of COVID-19 in relapsing forms of multiple sclerosis (RMS) patients treated with
The Pharma Data
OCTOBER 6, 2021
Adds 185,000 litres of biopharmaceutical production capacity High degree of digitalization and automation through smart technologies and artificial intelligence applications Multi-product setup enables production of a large variety of molecule formats Investment of more than 700 million EUR, creating 500 new jobs. Boehringer Ingelheim today inaugurated its state-of-the-art biopharmaceutical production facility Large Scale Cell Culture (LSCC) in Vienna, Austria.
Drug Patent Watch
OCTOBER 5, 2021
Annual Drug Patent Expirations for GENVOYA Genvoya is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from two suppliers. There are thirteen…. The post New patent for Gilead Sciences drug GENVOYA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 5, 2021
This chart shows the pharmaceutical companies with the most elixir dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most elixir dosed drugs…. The post Which pharmaceutical companies have the most elixir dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
144 
Let's personalize your content